Abstract:
Method and systems that provide improved cell handling and assays in microfluidic systems and devices particularly using lateral cell trapping and methods of fabrication of the same.
Abstract:
The present disclosure provides methods involving use of BIN1 expression levels, in heart tissue, in evaluating the risk of cardiac mortality in a patient diagnosed with congestive heart failure. The methods finds use in evaluating patients who are heart transplant candidates, as well as in assessing efficacy of treatment in congestive heart failure patients.
Abstract:
The present disclosure provides methods involving use of BIN1 expression levels, in heart tissue, in evaluating the risk of cardiac mortality in a patient diagnosed with congestive heart failure. The methods finds use in evaluating patients who are heart transplant candidates, as well as in assessing efficacy of treatment in congestive heart failure patients.
Abstract:
The present disclosure provides methods involving use of BIN1 protein levels in biological fluid of a subject in evaluating cardiac health of the subject. The method provided herein may be used to predict a risk of a poor outcome in a subject. The methods also find use in evaluating subjects for assessing patients diagnosed with heart failure. These methods are also useful in assessing therapy options and efficacy of treatment in heart failure patients.
Abstract:
The present disclosure provides methods involving use of BIN1 protein levels in biological fluid of a subject in evaluating cardiac health of the subject. The method provided herein may be used to predict a risk of a poor outcome in a subject. The methods also find use in evaluating subjects for assessing patients diagnosed with heart failure. These methods are also useful in assessing therapy options and efficacy of treatment in heart failure patients.
Abstract:
Method and systems that provide improved cell handling and assays in microfluidic systems and devices particularly using lateral cell trapping and methods of fabrication of the same.
Abstract:
The present disclosure provides methods involving use of BIN1 protein levels in biological fluid of a subject in evaluating cardiac health of the subject. The method provided herein may be used to predict a risk of a poor outcome in a subject. The methods also find use in evaluating subjects for assessing patients diagnosed with heart failure. These methods are also useful in assessing therapy options and efficacy of treatment in heart failure patients.
Abstract:
The present disclosure provides methods involving use of BIN1 expression levels, in heart tissue, in evaluating the risk of cardiac mortality in a patient diagnosed with congestive heart failure. The methods finds use in evaluating patients who are heart transplant candidates, as well as in assessing efficacy of treatment in congestive heart failure patients.